Zacks Research Estimates Longeveron FY2028 Earnings

Longeveron Inc. (NASDAQ:LGVN) – Investment analysts at Zacks Research issued their FY2028 earnings estimates for shares of Longeveron in a note issued to investors on Tuesday, February 17th. Zacks Research analyst B. Sorensen forecasts that the company will earn ($1.65) per share for the year. The consensus estimate for Longeveron’s current full-year earnings is ($3.69) per share.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Longeveron in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Longeveron currently has a consensus rating of “Hold” and a consensus target price of $6.50.

Longeveron Stock Performance

LGVN stock opened at $0.56 on Thursday. The business has a 50-day simple moving average of $0.56 and a two-hundred day simple moving average of $0.71. The company has a market capitalization of $11.98 million, a P/E ratio of -0.53 and a beta of 0.21. Longeveron has a 52-week low of $0.49 and a 52-week high of $1.92.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Longeveron stock. XTX Topco Ltd bought a new stake in shares of Longeveron Inc. (NASDAQ:LGVN) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned about 0.32% of Longeveron at the end of the most recent reporting period. 10.01% of the stock is owned by institutional investors.

Longeveron Company Profile

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.